

Independent Medical Advisers Prescribing and Dispensing of Tamiflu Terms and Conditions

Registration for Pandemic Influenza prescription is subject to the following Terms and Conditions.

Availability of treatment is conditional upon formal acceptance of these Terms and Conditions. All individuals wishing to participate in the Programme must confirm via their on-line Registration that they have read and agreed to these Terms and Conditions.

The term "IMA" in these terms and conditions means Independent Medical Advisers Limited unless stated to the contrary.

Personal Information

In order to comply with its licence and with General Medical Council guidelines, it is necessary for individuals to provide to IMA information about their medical history. It will not be possible for Tamiflu to be prescribed unless this information is provided to IMA Ltd. This information will be held in confidence by IMA, and will only be provided to those who need the information in order to generate a prescription.

Honest provision of information

Information provided by individuals must be true and up to date.

Accuracy and honesty in providing information is vitally important in order to ensure that Tamiflu is appropriately prescribed. Also, IMA reserves the right to refuse treatment if it is of the belief that an individual has not been open and honest in providing information.

Strictly for personal usage

Any Tamiflu that is provided under the Programme is only to be used by the person for whom it is

prescribed. Sale or redistribution of the Tamiflu to any other person by an individual or other member of his/her household is forbidden.

No Warranty

IMA gives no warranty or undertaking that any treatment provided under the Programme will be effective

Limitation of Liability

In so far as it is permitted by law IMA cannot accept any liability for death, personal injury or loss in the event of incorrect information being provided to it under the Programme.

Security of provided Tamiflu medication

Individuals agree to maintain any Tamiflu supplied to them in a safe and secure manner until usage is required. Tamiflu should not be left in an accessible area in the home, but in a secure cupboard or similar place and out of children's reach.

Use of Tamiflu

Tamiflu is to be used according to advice provided by the Medical team at IMA Ltd. and in accordance with Tamiflu's licenced indications. This includes completing the full course of treatment, as failure to do so may cause the development of resistant strains in the wider population. The Patient Information Leaflet should be read before Tamiflu is taken.

Data disclosure

Personal information about individuals will be kept in confidence by IMA Ltd., but by applying to participate in the Programme individuals agree that such information may be provided to other people who need the information in order to generate a prescription of Tamiflu.